CRISPR-based detection repurposes the same molecular machinery behind gene editing into a diagnostic tool that can identify tiny amounts of DNA or RNA in a sample, often in under an hour and sometimes with nothing more than a paper strip to read the result. The trick lies in a quirk of certain CRISPR enzymes: when they find and bind their programmed target sequence, they start indiscriminately shredding nearby nucleic acids. That seemingly destructive side effect turns out to be the perfect engine for a biosensor. Combined with signal reporters and pre-amplification steps, this collateral-cleavage behavior now powers platforms designed to detect viruses, bacteria, cancer biomarkers, crop pathogens, and antibiotic-resistance genes across clinical and field settings.
How Collateral Cleavage Becomes a Diagnostic Signal
Most people associate CRISPR with gene editing, where an enzyme like Cas9 is guided by a short RNA to cut a precise spot in the genome. Detection-focused CRISPR systems use a different set of enzymes, primarily Cas12 and Cas13, that share the ability to locate a specific nucleic acid target but then do something Cas9 does not: once they lock onto the target, they enter a hyperactive state and begin chopping up single-stranded nucleic acids nearby, with no regard for sequence. Researchers recognized this behavior could be harnessed if the sample also contained custom-built reporter molecules, short nucleic acid strands attached to a fluorescent tag or a label visible on a test strip. When the target pathogen’s genetic material is present, the CRISPR enzyme activates, destroys the reporters, and the freed tags produce a measurable signal. When the target is absent, the enzyme stays dormant and the reporters remain intact.
1PubMed Central. Three New Cs for CRISPR: Collateral, Communicate, CooperateCas13 targets RNA and chews up surrounding single-stranded RNA upon activation, while Cas12 targets DNA and degrades surrounding single-stranded DNA. This distinction matters because it lets researchers choose the right enzyme for whatever nucleic acid they need to find: an RNA virus like SARS-CoV-2, a DNA pathogen like human papillomavirus, or even a short stretch of tumor-shed DNA floating in blood.
2PubMed Central. CRISPR-based diagnostics for infectious diseases: mechanisms, advancements and clinical transformation prospectsSHERLOCK and DETECTR, the Two Flagship Platforms
The two best-known CRISPR diagnostic platforms are SHERLOCK and DETECTR, each built around a different Cas enzyme. SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) pairs Cas13 with an isothermal pre-amplification step called recombinase polymerase amplification (RPA) to boost the amount of target nucleic acid before the CRISPR enzyme goes to work. The result is an assay with attomolar sensitivity, meaning it can pick up vanishingly small quantities of target material. SHERLOCK provides results in under an hour, with setup taking less than 15 minutes, and its output can be read by fluorescence or by a simple color change visible to the naked eye.
3PubMed Central. SHERLOCK: nucleic acid detection with CRISPR nucleasesDETECTR (DNA Endonuclease-Targeted CRISPR Trans Reporter) takes a parallel approach using Cas12a instead. It was first demonstrated for detection of human papillomavirus in patient samples and also achieves attomolar sensitivity when combined with isothermal amplification.
4PubMed Central. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activityBoth platforms share the same general workflow: amplify the target, let the CRISPR enzyme find it, and read the signal from destroyed reporters. Where they differ is in which nucleic acid type they handle most naturally and in the specific amplification and readout chemistries they pair with. Other platforms such as CARMEN and CRISPR-Chip have extended this basic concept in various directions, but SHERLOCK and DETECTR remain the most widely studied and cited.
5PubMed Central. CRISPR-Cas systems for diagnosing infectious diseasesHow CRISPR Detection Stacks Up Against PCR
Quantitative PCR remains the gold standard for laboratory nucleic acid detection, and its raw sensitivity is hard to beat. In a head-to-head comparison, qPCR reached a detection limit as low as 0.5 copies per microliter, edging ahead of two-step CRISPR assays using Cas12a or Cas13a (both around 1 copy per microliter) and well ahead of one-step CRISPR methods. But qPCR needed over an hour to finish and required a thermocycler, a specialized and expensive piece of lab equipment. The CRISPR two-step methods completed both amplification and detection in about 15 minutes total.
6Biomedical Instrumentation. From PCR to CRISPR: Comparing the performance of different nucleic acid detection technologiesThe speed and simplicity advantages are what make CRISPR detection compelling for settings where PCR is impractical. During the COVID-19 pandemic, a DETECTR-based lateral flow assay for SARS-CoV-2 delivered results in under 40 minutes with 95% positive predictive agreement and 100% negative predictive agreement compared to the CDC’s RT-PCR test.
7Nature Biotechnology. CRISPR–Cas12-based detection of SARS-CoV-2A multicenter study across three Dutch hospitals tested DETECTR on 378 patient samples and found roughly 95% concordance with qRT-PCR, with both methods missing a comparable number of positive cases.
8The Journal of Infectious Diseases. Rapid, Sensitive, and Specific Severe Acute Respiratory Syndrome Coronavirus 2 Detection: A Multicenter Comparison Between Standard Quantitative Reverse-Transcriptase Polymerase Chain Reaction and CRISPR-Based DETECTRAn automated CRISPR-SARS-CoV-2 test evaluated against RT-PCR showed 98.2% sensitivity and 100% specificity, with no statistically significant difference in sensitivity between the two methods, while offering lower cost and shorter turnaround.
9PubMed Central. Evaluation of an automated CRISPR-based diagnostic tool for rapid detection of COVID-19The trade-off, in short: PCR squeezes out slightly better sensitivity in controlled lab conditions and remains the regulatory reference point. CRISPR-based assays trade a small sensitivity margin for major gains in speed, portability, and cost, which matters enormously in resource-limited clinics, field hospitals, and outbreak response.
Infectious Disease Applications Beyond COVID
While the pandemic served as the highest-profile proving ground, CRISPR detection tools are being developed for a wide range of pathogens. A one-step assay combining isothermal amplification with Cas12b was designed to detect monkeypox virus, completing the entire process in 40 minutes from extracted nucleic acid. Its limit of detection was 6.5 copies per reaction, it showed no cross-reactivity with other viruses including herpes simplex, Epstein-Barr, and enterovirus, and when tested on 113 clinical samples it achieved 100% sensitivity and 100% specificity compared to qPCR.
10PubMed Central. Rapid visual detection of Monkeypox virus by one-step LAMP-CRISPR/Cas12b assayCRISPR detection has also been paired with amplification to diagnose leishmaniasis, a parasitic disease prevalent in tropical regions where lab infrastructure is often scarce. Coupling LAMP amplification with Cas12a detection was specifically aimed at reducing false positives that LAMP alone sometimes produces, because the CRISPR step adds a second layer of sequence verification.
11PubMed Central. LAMP-coupled CRISPR-Cas12a assays: A promising new tool for molecular diagnosis of leishmaniasisAnother direction is antimicrobial resistance surveillance. FLASH, a method using CRISPR guide RNAs to enrich resistance gene sequences before next-generation sequencing, was able to identify every resistance gene found by standard sequencing in clinical Staphylococcus aureus isolates.
12Nucleic Acids Research. FLASH: a next-generation CRISPR diagnostic for multiplexed detection of antimicrobial resistance sequencesA related method applied CRISPR-Cas9-enriched sequencing to wastewater samples and found up to 1,189 more antibiotic resistance genes and up to 61 more gene families at low abundances than standard sequencing, including clinically important beta-lactamase genes. The approach lowered the detection limit by roughly a full order of magnitude.
13bioRxiv. Enhanced detection for antibiotic resistance genes in wastewater samples using a CRISPR-enriched metagenomic methodCancer Biomarker Detection
CRISPR-based sensors are finding a growing role in cancer diagnostics, particularly for picking up circulating tumor DNA (ctDNA) and microRNAs shed by tumors into blood and other body fluids. These biomarkers float in extremely low concentrations amid a sea of normal DNA, so any detection method needs to be both sensitive and capable of distinguishing single-base mutations from wild-type sequences.
An electrochemical sensor using a catalytically dead version of Cas9 (dCas9) demonstrated the ability to detect mutant ctDNA at concentrations as low as a few femtomolar, even when the mutant fragment constituted just 0.001% of the total DNA, meaning roughly 1 mutant copy per 100,000 normal copies. When tested on blood samples from patients with non-small cell lung cancer, the sensor accurately identified the relevant mutations.
14Analytical Chemistry. CRISPR/dCas9-Mediated Specific Molecular Assembly Facilitates Genotyping of Mutant Circulating Tumor DNAMicroRNAs are another promising target. A Cas12a-based fluorescence biosensor designed to detect miR-21, a microRNA linked to lung cancer, achieved a detection limit of 161 femtomolar and was able to distinguish cancer patients from healthy individuals using exosome-derived samples.
15Microchemical Journal. CRISPR/Cas12a-based fluorescence biosensor for detection of exosomal miR-21 derived from lung cancerA Cas13a-based system took a different approach, encapsulating CRISPR sensing components inside liposomes that fuse directly with tumor-derived extracellular vesicles. This allowed researchers to count the fraction of vesicles carrying miR-21-5p without needing to extract or amplify the RNA first. In ovarian cancer samples, roughly 2 to 10% of vesicles were positive, significantly higher than the less than 0.65% found in benign samples.
16PubMed Central. CRISPR/Cas13a-Based MicroRNA Detection in Tumor-Derived Extracellular VesiclesA dual-amplification biosensor using Cas12a demonstrated a detection limit of 1.35 femtomolar for miRNA-221 and was able to differentiate miRNA expression profiles across various cell types, supporting cell classification based on miRNA signatures. Importantly, the same platform was validated with a second target (miRNA-155), suggesting it is not locked to a single biomarker.
17PubMed. Dual-Amplification CRISPR Biosensor for Ultrasensitive miRNA Detection: A Powerful Tool for Cancer and Immune MonitoringAgriculture, Food Safety, and Environmental Monitoring
The appeal of CRISPR diagnostics in agriculture is straightforward: farmers and food-safety inspectors need fast answers in the field, not days later from a distant lab. CRISPR-based tools offer advantages over traditional methods like PCR and next-generation sequencing for on-site testing because they can operate without expensive equipment and still deliver high specificity.
18PubMed. CRISPR/Cas-Based Diagnostics in Agricultural ApplicationsOne recent assay demonstrated detection of wheat stripe rust directly from crude leaf samples within 40 minutes, identifying infections six days before visible symptoms appeared. That kind of early warning could allow targeted treatment of a small patch rather than blanket spraying of an entire field.
19Angewandte Chemie. In‐Field Molecular Diagnostics of Plant Pathogens Using Bioluminescent CRISPR‐Guided Caspase AssayFor food safety, a Cas12a-based method was developed for rapid detection of pathogenic E. coli strains, targeting isolates from livestock samples. The goal is a versatile platform easily adaptable for surveillance of pathogens that threaten both human health and animal production.
20PubMed Central. Rapid detection of pathogenic E. coli based on CRISPR Cas systemWater quality monitoring is another area where portability matters. A portable one-pot CRISPR/Cas assay called CAMERA was validated in spiked lake water and hydroponic lettuce samples with accuracy in the range of roughly 95 to 110% recovery and strong reproducibility. The system integrates sample processing, amplification, and detection into a single workflow that requires no specialized lab equipment.
21Chemical Engineering Journal. Portable one-pot CRISPR/Cas assay with multifunctional membrane pretreatment for ultra-sensitive detection of waterborne pathogensTesting for Multiple Targets at Once
One of the most useful advances in CRISPR diagnostics is multiplexing: the ability to detect several different targets in a single reaction. This matters for practical scenarios where you want to know not just whether a patient has one specific virus but which of several possible infections might be causing their symptoms, or whether a sample contains multiple drug-resistance genes.
The second version of SHERLOCK (SHERLOCKv2) achieved simultaneous detection of four targets by exploiting the fact that different Cas13 enzymes from different bacterial species prefer to cut at different two-nucleotide sequences. By pairing each enzyme with a reporter containing its preferred cleavage site, researchers could read four independent signals from one tube.
22PubMed Central. Multiplexed CRISPR-based Methods for Pathogen Nucleic Acid DetectionAn alternative strategy achieves multiplexed detection using just a single Cas protein. By integrating a strand-displacement reaction that produces target-specific reporters, researchers demonstrated single-nucleotide resolution for multiple targets without needing an arsenal of different Cas enzymes.
23PubMed. Multiplexed CRISPR-Based Nucleic Acid Detection Using a Single Cas ProteinMultiplexed lateral flow strips have also been designed using Cas12a and Cas13a together in an orthogonal system, where each enzyme’s activation and cleavage activity feeds into a separate readout line on the same strip, effectively eliminating interference between channels.
24Sensors and Actuators B: Chemical. Multiplexed lateral flow assay integrated with orthogonal CRISPR-Cas system for SARS-CoV-2 detectionMoving Toward At-Home and Point-of-Care Testing
Getting CRISPR diagnostics out of the lab and into the hands of non-experts is arguably the most consequential frontier. Several teams are combining CRISPR chemistry with microfluidic chips and smartphone readouts. One system called R-CHIP integrates amplification, CRISPR detection, and hand-driven microfluidics into a portable package that goes from sample to result in under an hour. Tested on 300 clinical samples for HPV-16 and HPV-18, it exceeded 95% accuracy, and a deep learning model on a paired smartphone further improved readout reliability.
25PubMed Central. Deep Learning-Enhanced Hand-Driven Microfluidic Chip for Multiplexed Nucleic Acid Detection Based on RPA/CRISPRA digital microfluidic platform paired CRISPR-Cas autocatalytic signal amplification with a smartphone camera to simultaneously detect two tumor biomarkers in saliva, using magnetic and electrowetting forces to move droplets through each reaction step on a small chip.
26Sensors and Actuators B: Chemical. A digital microfluidic platform based on CRISPR-Cas autocatalysis signal amplification for detection of two tumor biomarkers in salivaPerhaps the most telling demonstration of how close CRISPR diagnostics are to consumer use: a wax-transition-based one-pot CRISPR assay for sexually transmitted infections was tested in a double-blinded study where eight untrained volunteers successfully identified STI targets across 33 clinical samples. The assay used a wax seal that melts at a set temperature to sequentially release reagents, removing the need for pipetting or lab training.
27PubMed. Phase Transition of Wax Enabling CRISPR Diagnostics for Automatic At-Home Testing of Multiple Sexually Transmitted Infection PathogensAmplification-free approaches are also under development. One platform uses a rationally designed DNA substrate to trigger autocatalytic signal amplification by Cas12a, eliminating the pre-amplification step entirely while keeping detection straightforward and inexpensive.
28ACS Omega. Rapid and Amplification-free Nucleic Acid Detection with DNA Substrate-Mediated Autocatalysis of CRISPR/Cas12aNew Enzymes Expanding the Toolkit
The CRISPR universe is not limited to Cas12 and Cas13. Researchers have discovered Cas14, a family of exceptionally small CRISPR nucleases found in uncultivated archaea, with proteins only 400 to 700 amino acids long, roughly half the size of Cas9. Despite their compact structure, Cas14 proteins can target single-stranded DNA without needing a specific flanking sequence, and their activation triggers the same collateral cleavage seen in Cas12. A Cas14-based DETECTR variant demonstrated high-fidelity genotyping of single-nucleotide polymorphisms, the kind of single-letter DNA differences that distinguish closely related virus strains or identify inherited disease variants.
29PubMed Central. Programmed DNA destruction by miniature CRISPR-Cas14 enzymesSmaller enzymes are easier to package, cheaper to produce, and potentially simpler to integrate into compact devices. As metagenomic surveys continue to uncover new CRISPR systems from environmental microbes, the diagnostic toolkit is likely to keep growing. Each new enzyme brings slightly different cleavage preferences, size characteristics, and temperature tolerances, giving assay designers more options to match the enzyme to the problem.
What Is Holding CRISPR Diagnostics Back
For all the impressive lab results, CRISPR-based diagnostics have not yet displaced PCR in most clinical workflows. Several barriers explain the gap. The attomolar sensitivity frequently reported in CRISPR diagnostic papers depends on a pre-amplification step like RPA, LAMP, or PCR itself. Without that boost, current enzyme kinetics and signal detection methods cannot reliably reach subfemtomolar concentrations, which is the range needed for applications like liquid biopsy, where tumor DNA circulates at extremely low levels.
30PubMed Central. Building the Future of Clinical Diagnostics: An Analysis of Potential Benefits and Current Barriers in CRISPR/Cas DiagnosticsAdding a pre-amplification step introduces its own problems. It increases complexity, adds reagents and time, and can compromise quantitative accuracy because the amplification itself is not perfectly linear. One-pot designs that combine amplification and CRISPR detection in the same tube simplify handling but tend to sacrifice some sensitivity because the two reaction systems can interfere with each other. In one comparison, a Cas12a one-step assay had a detection limit of 10 copies per microliter, ten times worse than the two-step version.
6Biomedical Instrumentation. From PCR to CRISPR: Comparing the performance of different nucleic acid detection technologiesRegulatory approval presents another hurdle. While CRISPR diagnostics do not face the same safety concerns as therapeutic gene editing, the regulatory landscape for any novel diagnostic platform is still complex. Agencies require extensive validation against established methods, and the diversity of CRISPR-based assay designs, each with different enzymes, amplification strategies, and readout formats, means there is no single streamlined path to approval.
31PubMed Central. Building the Future of Clinical Diagnostics: An Analysis of Potential Benefits and Current Barriers in CRISPR/Cas Diagnostics – Section: Current Hurdles in AdoptionSupply chain and manufacturing scale are quieter challenges. Producing CRISPR enzymes and guide RNAs at the volumes needed for mass-market diagnostics requires protein expression and purification infrastructure that is well established for some reagents but not yet for all the Cas variants being explored. Cold-chain requirements for enzyme stability also complicate distribution to the low-resource settings where these tools would have the greatest impact, though innovations like the wax-sealed assay described earlier are explicitly designed to address stability.
None of these barriers look permanent. The trajectory is clearly moving from proof-of-concept toward real-world deployment, with each generation of assay addressing a specific bottleneck, whether that is amplification dependence, multiplexing limitations, or the need for trained operators. The technology is likely to carve out a niche alongside PCR rather than replace it, excelling in situations where speed, portability, and low cost matter more than extracting the last fraction of sensitivity from a well-equipped lab.